Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Purchased by Credit Suisse AG

Credit Suisse AG boosted its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Rating) by 2.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,294 shares of the company’s stock after purchasing an additional 959 shares during the period. Credit Suisse AG owned approximately 0.09% of Prestige Consumer Healthcare worth $2,157,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC grew its stake in shares of Prestige Consumer Healthcare by 474.7% during the third quarter. Quadrant Capital Group LLC now owns 1,092 shares of the company’s stock valued at $54,000 after acquiring an additional 902 shares in the last quarter. WINTON GROUP Ltd acquired a new stake in shares of Prestige Consumer Healthcare during the third quarter valued at about $462,000. ExodusPoint Capital Management LP grew its stake in shares of Prestige Consumer Healthcare by 209.7% during the third quarter. ExodusPoint Capital Management LP now owns 32,420 shares of the company’s stock valued at $1,615,000 after acquiring an additional 21,951 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Prestige Consumer Healthcare by 2.3% during the third quarter. Dimensional Fund Advisors LP now owns 3,558,317 shares of the company’s stock valued at $177,312,000 after acquiring an additional 79,248 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Prestige Consumer Healthcare by 67.9% during the third quarter. Tower Research Capital LLC TRC now owns 10,213 shares of the company’s stock valued at $509,000 after acquiring an additional 4,130 shares in the last quarter. 99.98% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $60.31 on Monday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.56 and a current ratio of 2.55. Prestige Consumer Healthcare Inc. has a one year low of $48.51 and a one year high of $67.45. The company’s 50-day simple moving average is $63.21 and its 200-day simple moving average is $58.02. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of 14.46, a PEG ratio of 1.80 and a beta of 0.56.

Prestige Consumer Healthcare (NYSE:PBH – Get Rating) last issued its earnings results on Thursday, February 2nd. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. Prestige Consumer Healthcare had a net margin of 18.97% and a return on equity of 12.65%. The firm had revenue of $275.50 million for the quarter, compared to analysts’ expectations of $273.84 million. During the same quarter last year, the company posted $0.99 earnings per share. Prestige Consumer Healthcare’s revenue was up .4% on a year-over-year basis. Equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Canaccord Genuity Group assumed coverage on Prestige Consumer Healthcare in a research note on Wednesday, November 16th. They set a “buy” rating and a $71.00 target price for the company. Oppenheimer reduced their price target on shares of Prestige Consumer Healthcare from $72.00 to $71.00 and set an “outperform” rating on the stock in a research report on Friday, February 17th. Finally, Canaccord Genuity Group began coverage on shares of Prestige Consumer Healthcare in a research report on Thursday, November 17th. They set a “buy” rating and a $71.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.75.

Prestige Consumer Healthcare Profile

(Get Rating)

Prestige Consumer Healthcare, Inc engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve.